ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,099.96
      1.02%
      US Tech 100
      17,244.80
      1.57%
      Dow Jones
      38,239.66
      0.40%
      Brent Oil
      88.165
      0.00%
      Bitcoin
      63,239.70
      -0.78%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. AMEX
      6. Citigroup Fdg (CTH)

      7. Citigroup Fdg (CTH) News

      CTH

      Citigroup Fdg (CTH)

      Citigroup Fdg
      		Date:
      Sort by:
       Showing the most relevant articles for your search:AMEX:CTH
      DateTimeSourceHeadlineSymbolCompany
      08/15/20166:00AMGlobeNewswireCynapsus Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allow...AMEX:CTHCitigroup Fdg
      07/18/20164:10PMGlobeNewswireCynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episod...AMEX:CTHCitigroup Fdg
      06/30/20168:00AMGlobeNewswireCynapsus Therapeutics Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients ...AMEX:CTHCitigroup Fdg
      05/30/20162:00AMGlobeNewswireCynapsus Therapeutics Announces Data Presentations at the European Academy of Neurology Annual MeetingAMEX:CTHCitigroup Fdg
      04/15/20166:00AMGlobeNewswireCynapsus Therapeutics Announces Data Presentations at the American Academy of Neurology Annual MeetingAMEX:CTHCitigroup Fdg
      12/08/20152:00AMGlobeNewswireCynapsus Therapeutics Announces Positive Data Presentations at World Congress on Parkinson's Disease and Related Disorders Me...AMEX:CTHCitigroup Fdg
      07/17/20144:15PMGlobeNewswireCynapsus Therapeutics Inc : Cynapsus Therapeutics Commences Phase 2 Clinical Trials in the United StatesAMEX:CTHCitigroup Fdg
      07/08/20141:00AMGlobeNewswireCynapsus Therapeutics Inc. : Cynapsus Therapeutics Awarded Second Grant from The Michael J. Fox Foundation for Parkinson's Re...AMEX:CTHCitigroup Fdg
      05/14/20146:00AMGlobeNewswireCynapsus Therapeutics Inc. : Cynapsus Announces No Buccal Mucosal Irritation in FDA Registration Study of APL-130277 for Park...AMEX:CTHCitigroup Fdg
      04/24/20146:00AMGlobeNewswireCynapsus Therapeutics Inc. : Cynapsus Announces Positive Results of CTH-104 Clinical Study of APL-130277 for Parkinson's Dise...AMEX:CTHCitigroup Fdg
      03/28/20146:00AMGlobeNewswireCynapsus Therapeutics Inc. : Cynapsus Announces Interim Summary Results of Human Healthy Volunteer Single 25mg Study for APL-...AMEX:CTHCitigroup Fdg
      01/13/20146:00AMGlobeNewswireCynapsus Therapeutics Inc. : Cynapsus Announces Completion of Human Healthy Volunteer Crossover Study Results for APL-130277AMEX:CTHCitigroup Fdg
      05/15/20131:00AMGlobeNewswireCynapsus Therapeutics Inc. : Cynapsus Therapeutics Publishes White Paper on Apomorphine for 'Off' Periods in Parkinson's Dise...AMEX:CTHCitigroup Fdg
      03/24/200611:00AMPR Newswire (US)American Stock Exchange Lists Citigroup Funding Inc.'s 7.5% Sequins Linked to UnitedHealth Group Inc.AMEX:CTH
       Showing the most relevant articles for your search:AMEX:CTH